Arterial Input Function Calculation in Dynamic Contrast-enhanced MRI: an in Vivo Validation Study Using Co-registered Contrast-enhanced Ultrasound Imaging

Overview

Journal Eur Radiol

Specialty Radiology

Date 2012 Jul 4

PMID 22752523

Citations 3

Authors

Hatef Mehrabian

Chaitanya Chandrana

Ian Pang

Rajiv Chopra

Anne L Martel

Affiliations

Soon will be listed here.

Abstract

Objectives: Developing a method of separating intravascular contrast agent concentration to measure the arterial input function (AIF) in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of tumours, and validating its performance in phantom and in vivo experiments.

Methods: A tissue-mimicking phantom was constructed to model leaky tumour vasculature and DCE-MR images of this phantom were acquired. An in vivo study was performed using tumour-bearing rabbits. Co-registered DCE-MRI and contrast-enhanced ultrasound (CEUS) images were acquired. An independent component analysis (ICA)-based method was developed to separate the intravascular component from DCE-MRI. Results were validated by comparing the time-intensity curves with the actual phantom and in vivo curves.

Results: Phantom study: the AIF extracted using ICA correlated well with the true intravascular curve. In vivo study: the AIFs extracted from DCE-MRI using ICA were very close to the true AIF. Intravascular component images were very similar to the CEUS images. The contrast onset times and initial wash-in slope of the ICA-derived AIF showed good agreement with the CEUS curves.

Conclusion: ICA has the potential to separate the intravascular component from DCE-MRI. This could eliminate the requirement for contrast medium uptake measurements in a major artery and potentially result in more accurate pharmacokinetic parameters.

Key Points: • Tumour response to therapy can be inferred from pharmacokinetic parameters. • Arterial input function (AIF) is required for pharmacokinetic modelling of tumours. • Independent component analysis has the potential to measure AIF inside the tumour. • AIF measurement is validated using contrast enhanced ultrasound and phantoms.

Citing Articles

The emerging potential of magnetic resonance imaging in personalizing radiotherapy for head and neck cancer: an oncologist's perspective.

Wong K, Panek R, Bhide S, Nutting C, Harrington K, Newbold K Br J Radiol. 2017; 90(1071):20160768.

PMID: 28256151 PMC: 5601510. DOI: 10.1259/bjr.20160768.

The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge.

Huang W, Chen Y, Fedorov A, Li X, Jajamovich G, Malyarenko D Tomography. 2016; 2(1):56-66.

PMID: 27200418 PMC: 4869732. DOI: 10.18383/j.tom.2015.00184.

A comparison of two methods for estimating DCE-MRI parameters via individual and cohort based AIFs in prostate cancer: a step towards practical implementation.

Fedorov A, Fluckiger J, Ayers G, Li X, Gupta S, Tempany C Magn Reson Imaging. 2014; 32(4):321-9.

PMID: 24560287 PMC: 3965600. DOI: 10.1016/j.mri.2014.01.004.

References

Koh T, Thng C, Ho J, Tan P, Rumpel H, Khoo J . Independent component analysis of dynamic contrast-enhanced magnetic resonance images of breast carcinoma: a feasibility study. J Magn Reson Imaging. 2008; 28(1):271-7. DOI: 10.1002/jmri.21391. View

Gossmann A, Helbich T, Kuriyama N, Ostrowitzki S, Roberts T, Shames D . Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging. 2002; 15(3):233-40. DOI: 10.1002/jmri.10072. View

Naish J, Kershaw L, Buckley D, Jackson A, Waterton J, Parker G . Modeling of contrast agent kinetics in the lung using T1-weighted dynamic contrast-enhanced MRI. Magn Reson Med. 2009; 61(6):1507-14. DOI: 10.1002/mrm.21814. View

Viallon M, Terraz S, Roland J, Dumont E, Becker C, Salomir R . Observation and correction of transient cavitation-induced PRFS thermometry artifacts during radiofrequency ablation, using simultaneous ultrasound/MR imaging. Med Phys. 2010; 37(4):1491-506. DOI: 10.1118/1.3309439. View

Curiel L, Huang Y, Vykhodtseva N, Hynynen K . Focused ultrasound treatment of VX2 tumors controlled by local harmonic motion. Phys Med Biol. 2009; 54(11):3405-19. DOI: 10.1088/0031-9155/54/11/009. View

Canet E, Douek P, Janier M, Bendid K, Amaya J, Millet P . Influence of bolus volume and dose of gadolinium chelate for first-pass myocardial perfusion MR imaging studies. J Magn Reson Imaging. 1995; 5(4):411-5. DOI: 10.1002/jmri.1880050407. View

Calamante F, Morup M, Hansen L . Defining a local arterial input function for perfusion MRI using independent component analysis. Magn Reson Med. 2004; 52(4):789-97. DOI: 10.1002/mrm.20227. View

Smith J, Sorensen A, Thrall J . Biomarkers in imaging: realizing radiology's future. Radiology. 2003; 227(3):633-8. DOI: 10.1148/radiol.2273020518. View

Hyvarinen A . Fast and robust fixed-point algorithms for independent component analysis. IEEE Trans Neural Netw. 2008; 10(3):626-34. DOI: 10.1109/72.761722. View

10.

Tofts P, Brix G, Buckley D, Evelhoch J, Henderson E, Knopp M . Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999; 10(3):223-32. DOI: 10.1002/(sici)1522-2586(199909)10:3<223::aid-jmri2>3.0.co;2-s. View

11.

Curiel L, Chopra R, Hynynen K . Progress in multimodality imaging: truly simultaneous ultrasound and magnetic resonance imaging. IEEE Trans Med Imaging. 2007; 26(12):1740-6. PMC: 2862902. DOI: 10.1109/tmi.2007.903572. View

12.

Weber W . Assessing tumor response to therapy. J Nucl Med. 2009; 50 Suppl 1:1S-10S. DOI: 10.2967/jnumed.108.057174. View

13.

Cheng H . Investigation and optimization of parameter accuracy in dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2008; 28(3):736-43. DOI: 10.1002/jmri.21489. View

14.

Korporaal J, van Vulpen M, van den Berg C, van der Heide U . Tracer kinetic model selection for dynamic contrast-enhanced computed tomography imaging of prostate cancer. Invest Radiol. 2011; 47(1):41-8. DOI: 10.1097/RLI.0b013e31821c0ea7. View

15.

Galbraith S, Maxwell R, Lodge M, Tozer G, Wilson J, Taylor N . Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol. 2003; 21(15):2831-42. DOI: 10.1200/JCO.2003.05.187. View

16.

Hamstra D, Rehemtulla A, Ross B . Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol. 2007; 25(26):4104-9. DOI: 10.1200/JCO.2007.11.9610. View

17.

Hyvarinen A, Oja E . Independent component analysis: algorithms and applications. Neural Netw. 2000; 13(4-5):411-30. DOI: 10.1016/s0893-6080(00)00026-5. View

18.

Chandrana C, Bevan P, Hudson J, Pang I, Burns P, Plewes D . Development of a platform for co-registered ultrasound and MR contrast imaging in vivo. Phys Med Biol. 2011; 56(3):861-77. DOI: 10.1088/0031-9155/56/3/020. View

19.

Hansen A, Pedersen H, Rostrup E, Larsson H . Partial volume effect (PVE) on the arterial input function (AIF) in T1-weighted perfusion imaging and limitations of the multiplicative rescaling approach. Magn Reson Med. 2009; 62(4):1055-9. DOI: 10.1002/mrm.22098. View

20.

Lu W, Rajapakse J . Approach and applications of constrained ICA. IEEE Trans Neural Netw. 2005; 16(1):203-12. DOI: 10.1109/TNN.2004.836795. View